428 related articles for article (PubMed ID: 24617977)
1. Effects of cross-sex hormone treatment on cortical thickness in transsexual individuals.
Zubiaurre-Elorza L; Junque C; Gómez-Gil E; Guillamon A
J Sex Med; 2014 May; 11(5):1248-61. PubMed ID: 24617977
[TBL] [Abstract][Full Text] [Related]
2. Cortical thickness in untreated transsexuals.
Zubiaurre-Elorza L; Junque C; Gómez-Gil E; Segovia S; Carrillo B; Rametti G; Guillamon A
Cereb Cortex; 2013 Dec; 23(12):2855-62. PubMed ID: 22941717
[TBL] [Abstract][Full Text] [Related]
3. Profound Changes in Sex Hormone Levels during Cross-Sex Hormone Therapy of Transsexuals do not Alter Serum Cholesterol Acceptor Capacity.
Wultsch A; Kaufmann U; Ott J; Stojakovic T; Scharnagl H; Stangl H; Strobl WM
J Sex Med; 2015 Jun; 12(6):1436-9. PubMed ID: 25854918
[TBL] [Abstract][Full Text] [Related]
4. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals.
Elbers JM; Asscheman H; Seidell JC; Frölich M; Meinders AE; Gooren LJ
J Clin Endocrinol Metab; 1997 Oct; 82(10):3267-70. PubMed ID: 9329351
[TBL] [Abstract][Full Text] [Related]
5. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.
Nota NM; Dekker MJHJ; Klaver M; Wiepjes CM; van Trotsenburg MA; Heijboer AC; den Heijer M
Andrologia; 2017 Aug; 49(6):. PubMed ID: 27561756
[TBL] [Abstract][Full Text] [Related]
6. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration.
Seiger R; Hahn A; Hummer A; Kranz GS; Ganger S; Woletz M; Kraus C; Sladky R; Kautzky A; Kasper S; Windischberger C; Lanzenberger R
Psychoneuroendocrinology; 2016 Dec; 74():371-379. PubMed ID: 27744092
[TBL] [Abstract][Full Text] [Related]
7. Cross sex hormone treatment is linked with a reversal of cerebral patterns associated with gender dysphoria to the baseline of cisgender controls.
Kilpatrick LA; Holmberg M; Manzouri A; Savic I
Eur J Neurosci; 2019 Oct; 50(8):3269-3281. PubMed ID: 30991464
[TBL] [Abstract][Full Text] [Related]
8. Effects of androgenization on the white matter microstructure of female-to-male transsexuals. A diffusion tensor imaging study.
Rametti G; Carrillo B; Gómez-Gil E; Junque C; Zubiaurre-Elorza L; Segovia S; Gomez A; Karadi K; Guillamon A
Psychoneuroendocrinology; 2012 Aug; 37(8):1261-9. PubMed ID: 22260939
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals.
Bunck MC; Giltay EJ; Diamant M; Gooren LJ; Teerlink T
Atherosclerosis; 2009 Sep; 206(1):245-50. PubMed ID: 19324362
[TBL] [Abstract][Full Text] [Related]
10. Cross-sex hormone therapy for gender dysphoria.
Fabris B; Bernardi S; Trombetta C
J Endocrinol Invest; 2015 Mar; 38(3):269-82. PubMed ID: 25403429
[TBL] [Abstract][Full Text] [Related]
11. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Toorians AW; Thomassen MC; Zweegman S; Magdeleyns EJ; Tans G; Gooren LJ; Rosing J
J Clin Endocrinol Metab; 2003 Dec; 88(12):5723-9. PubMed ID: 14671159
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
van Kesteren PJ; Asscheman H; Megens JA; Gooren LJ
Clin Endocrinol (Oxf); 1997 Sep; 47(3):337-42. PubMed ID: 9373456
[TBL] [Abstract][Full Text] [Related]
13. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.
Smith KP; Madison CM; Milne NM
Pharmacotherapy; 2014 Dec; 34(12):1282-97. PubMed ID: 25220381
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals.
Caanen MR; Schouten NE; Kuijper EAM; van Rijswijk J; van den Berg MH; van Dulmen-den Broeder E; Overbeek A; van Leeuwen FE; van Trotsenburg M; Lambalk CB
Hum Reprod; 2017 Jul; 32(7):1457-1464. PubMed ID: 28505246
[TBL] [Abstract][Full Text] [Related]
15. Cortical activation during mental rotation in male-to-female and female-to-male transsexuals under hormonal treatment.
Carrillo B; Gómez-Gil E; Rametti G; Junque C; Gomez A; Karadi K; Segovia S; Guillamon A
Psychoneuroendocrinology; 2010 Sep; 35(8):1213-22. PubMed ID: 20219285
[TBL] [Abstract][Full Text] [Related]
16. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of white matter volume between postoperative female-to-male transsexuals and healthy female.
Kim GW; Kim YH; Park K; Jeong GW
Int J Impot Res; 2019 Nov; 31(6):432-438. PubMed ID: 30679768
[TBL] [Abstract][Full Text] [Related]
18. Conjectures concerning cross-sex hormone treatment of aging transsexual persons.
Gooren L; Lips P
J Sex Med; 2014 Aug; 11(8):2012-9. PubMed ID: 24775178
[TBL] [Abstract][Full Text] [Related]
19. Neuroimaging differences in spatial cognition between men and male-to-female transsexuals before and during hormone therapy.
Schöning S; Engelien A; Bauer C; Kugel H; Kersting A; Roestel C; Zwitserlood P; Pyka M; Dannlowski U; Lehmann W; Heindel W; Arolt V; Konrad C
J Sex Med; 2010 May; 7(5):1858-67. PubMed ID: 19751389
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.
van Kesteren P; Lips P; Gooren LJ; Asscheman H; Megens J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):347-54. PubMed ID: 9578826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
